tRNA-derived small RNA 3′U-tRFValCAC promotes tumour migration and early progression in ovarian cancer

Panoutsopoulou, Konstantina; Magkou, Paraskevi; Dreyer, Tobias; Dorn, Julia; Obermayr, Eva; Mahner, Sven; Gorp, Toon Van; Braicu, Ioana; Magdolen, Viktor; Zeillinger, Robert; Avgeris, Margaritis; Scorilas, Andreas

doi:10.1016/j.ejca.2022.11.033

Cited by 8 publications

(7 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…38 In addition, 3′ U-tRF ValCAC promotes tumor migration in ovarian cancer by regulating cell proliferation and adhesion. 39 According to previous studies, some tsRNAs can influence cancer progression through the protein sponge mechanism. 12,31 Tao et al…”

Section: Discussionmentioning

confidence: 99%

“…Several studies have suggested that tsRNAs may promote or suppress cancer according to different internal mechanisms. 38,39 tRF-Leu-CAG is derived from the 5′ ends of two mature tRNAs with the same structural and functional characteristics as miRNAs, and tRF-Leu-CAG interacts with miR-137 or miR-32 to jointly regulate the expression of the gene AURKA in cells, thereby affecting the progression of nonsmall cell carcinoma. 38 In addition, 3′ U-tRF ValCAC promotes tumor migration in ovarian cancer by regulating cell proliferation and adhesion.…”

Section: Discussionmentioning

confidence: 99%

“…tRF‐Leu‐CAG is derived from the 5′ ends of two mature tRNAs with the same structural and functional characteristics as miRNAs, and tRF‐Leu‐CAG interacts with miR‐137 or miR‐32 to jointly regulate the expression of the gene AURKA in cells, thereby affecting the progression of nonsmall cell carcinoma 38 . In addition, 3′ U‐tRF ValCAC promotes tumor migration in ovarian cancer by regulating cell proliferation and adhesion 39 . According to previous studies, some tsRNAs can influence cancer progression through the protein sponge mechanism 12,31 .…”

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

A comprehensive evaluation of serum tRF‐29‐R9J8909NF5JP as a novel diagnostic and prognostic biomarker for gastric cancer

Li,

Zhang,

et al. 2023

Molecular Carcinogenesis

View full text Add to dashboard Cite

Gastric cancer (GC) is a common malignant digestive system tumor. Since the early symptoms of GC are usually vague and the positive rate of common biomarkers of GC is low, it is of urgent need to find new biomarkers with good sensitivity and specificity to screen and diagnose GC patients. The tRNA‐derived small RNAs (tsRNAs) are emerging small noncoding RNAs that play an essential role in cancer progression. In this study, we explored whether novel tsRNAs have the potential to serve as biomarkers for GC. Three tsRNAs significantly upregulated in GC were screened by the tsRFun database. The expression level of tRF‐29‐R9J8909NF5JP was detected by real‐time fluorescence quantitative polymerase chain reaction. Agarose gel electrophoresis and Sanger sequencing were used to verify the characteristics of tRF‐29‐R9J8909NF5JP. The receiver operating characteristic (ROC) curve was used to evaluate the diagnostic efficacy of tRF‐29‐R9J8909NF5JP. The χ2 test was used to analyze the correlation between tRF‐29‐R9J8909NF5JP expression level and clinicopathological parameters. Kaplan–Meier survival curves were used to analyze the correlation between tRF‐29‐R9J8909NF5JP expression levels and survival time of GC patients. In this study, the expression level of tRF‐29‐R9J8909NF5JP was significantly increased in GC tissues. The expression level of tRF‐29‐R9J8909NF5JP was considerably higher in the serum of GC patients than in the serum of gastritis patients and in the serum of healthy donors, and the expression level of tRF‐29‐R9J8909NF5JP was significantly decreased in the serum of GC patients after surgery. In addition, the χ2 test showed that the expression level of tRF‐29‐R9J8909NF5JP in GC serum was correlated with differentiation grade, T‐stage, lymph node metastasis, tumor node metastasis stage, and neurological/vascular invasion. The results of the survival curve showed that the high expression of serum tRF‐29‐R9J8909NF5JP was associated with a low survival rate. ROC analysis showed that serum tRF‐29‐R9J8909NF5JP had higher diagnostic efficiency than common GC biomarkers, and the diagnostic efficiency was further improved by combining them. At the end of the study, we predicted the downstream of tRF‐29‐R9J8909NF5JP. The expression level of tRF‐29‐R9J8909NF5JP in the serum of GC patients can effectively identify GC patients and has higher efficacy than conventional biomarkers. In addition, serum tRF‐29‐R9J8909NF5JP can monitor the postoperative condition of GC patients, suggesting that it has the potential to become a biomarker for GC.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

A comprehensive evaluation of serum tRF‐29‐R9J8909NF5JP as a novel diagnostic and prognostic biomarker for gastric cancer

Li,

Zhang,

et al. 2023

Molecular Carcinogenesis

View full text Add to dashboard Cite

show abstract

“…For example, tRF3008A overexpression inhibits CRC cell's ability to proliferate, migrate and invade by suppressing endogenous FOXK1 , whereas tRF‐17‐79MP9PP targets THBS1 to repress the TGFb1/Smad3 signalling pathway in breast cancer cells 18,19 . Additionally, tsRNAs have potential therapeutic, diagnostic and prognostic value in various cancers such as that colorectal, 18 pancreas, 20 breast, 21 liver 22 and ovaries 23 . However, no studies currently report the relationship between tsRNA and cancer cell radiation sensitivity.…”

Section: Introductionmentioning

confidence: 99%

“…18,19 Additionally, tsRNAs have potential therapeutic, diagnostic and prognostic value in various cancers such as that colorectal, 18 pancreas, 20 breast, 21 liver 22 and ovaries. 23 However, no studies currently report the relationship between tsRNA and cancer cell radiation sensitivity. MAPK interacting serine/threonine kinase-1 (MKNK1) is a member of the MAPK subfamily that acts as a critical regulatory factor in the MAPK signalling pathway.…”

mentioning

confidence: 99%

A tRF‐5a fragment that regulates radiation resistance of colorectal cancer cells by targeting MKNK1

Huang,

Chen,

et al. 2023

J Cellular Molecular Medi

View full text Add to dashboard Cite

Radiotherapy serves as a crucial strategy in the treatment of colorectal cancer (CRC). However, its efficacy is often hindered by the challenge of radiation resistance. Although the literature suggests that some tRNA‐derived small RNAs (tsRNAs) are associated with various cancers, studies reporting the relationship of tsRNAs with cancer cell radiosensitivity have not been published yet. In our study, we utilized tsRNAs sequencing to predict differentially expressed tsRNAs in two CRC cells and their radioresistant cells, and 10 tsRNAs with significant differences in expression were validated by qPCR. The target genes of tRF‐16‐7X9PN5D were predicted and verified by the bioinformatics, dual‐luciferase reporter gene assay and western blotting analyses. Wound healing, colony formation, transwell invasion and CCK‐8 assays were performed to detect the effects of tRF‐16‐7X9PN5D on cell function and radiosensitivity. Western blotting evaluated the relationship between tRF‐16‐7X9PN5D and the MKNK‐eIF4E axis. Our findings demonstrated that tRF‐16‐7X9PN5D expression was substantially downregulated in radioresistant CRC cells. Furthermore, tRF‐16‐7X9PN5D could promote CRC cells' ability to proliferate, migrate, invade and obtain radiation resistance by targeting MKNK1. Finally, tRF‐16‐7X9PN5D could regulate eIF4E phosphorylation via MKNK1. This investigation indicated that tRF‐16‐7X9PN5D has an essential regulatory role in the radiation resistance of CRC by directly targeting MKNK1, and may be a new pathway for regulating the CRC radiosensitivity.

show abstract

tRNA modifications and tRNA-derived small RNAs: new insights of tRNA in human disease

Wu,

Li,

Khan

et al. 2024

Cell Biol Toxicol

View full text Add to dashboard Cite

tRNAs are codon decoders that convert the transcriptome into the proteome. The field of tRNA research is excited by the increasing discovery of specific tRNA modifications that are installed at specific, evolutionarily conserved positions by a set of specialized tRNA-modifying enzymes and the biogenesis of tRNA-derived regulatory fragments (tsRNAs) which exhibit copious activities through multiple mechanisms. Dysregulation of tRNA modification usually has pathological consequences, a phenomenon referred to as "tRNA modopathy". Current evidence suggests that certain tRNA-modifying enzymes and tsRNAs may serve as promising diagnostic biomarkers and therapeutic targets, particularly for chemoresistant cancers. In this review, we discuss the latest discoveries that elucidate the molecular mechanisms underlying the functions of clinically relevant tRNA modifications and tsRNAs, with a focus on malignancies. We also discuss the therapeutic potential of tRNA/tsRNA-based therapies, aiming to provide insights for the development of innovative therapeutic strategies. Further efforts to unravel the complexities inherent in tRNA biology hold the promise of yielding better biomarkers for the diagnosis and prognosis of diseases, thereby advancing the development of precision medicine for health improvement.

show abstract

tRNA-derived small RNA 3′U-tRFValCAC promotes tumour migration and early progression in ovarian cancer

Cited by 8 publications

References 38 publications

A comprehensive evaluation of serum tRF‐29‐R9J8909NF5JP as a novel diagnostic and prognostic biomarker for gastric cancer

A comprehensive evaluation of serum tRF‐29‐R9J8909NF5JP as a novel diagnostic and prognostic biomarker for gastric cancer

A tRF‐5a fragment that regulates radiation resistance of colorectal cancer cells by targeting MKNK1

tRNA modifications and tRNA-derived small RNAs: new insights of tRNA in human disease

Contact Info

Product

Resources

About